EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY-NC-ND 4.0

Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]

Robert Roskoski

Pharmacological Research · 2026-11 · 109738

DOI: 10.1016/j.phrs.2026.109738 ↗

Kurz gefasst

Korrektur in der Zeitschrift Pharmacological Research, 2026-11. Verfasst von Robert Roskoski. Beteiligte Einrichtung: Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: rrj@brimr.org. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: rrj@brimr.org.

Zitieren

APA

Roskoski, R. (2026). Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]. Pharmacological Research, 109738. https://doi.org/10.1016/j.phrs.2026.109738

Vancouver

Roskoski R. Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]. Pharmacological Research. 2026:109738. doi:10.1016/j.phrs.2026.109738

BibTeX
@article{Roskoski2026,
  author = {Roskoski, Robert},
  title = {Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]},
  journal = {Pharmacological Research},
  year = {2026},
  pages = {109738},
  doi = {10.1016/j.phrs.2026.109738}
}
Kostenlos starten →